A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

Sorafenib is a multi-kinase inhibitor with antiangiogenic and antiproliferative activity. The activity of sorafenib in progressive hormone-refractory prostate cancer (HRPC) patients was investigated in a phase II clinical study. Progressive HRPC patients received sorafenib 400 mg bid p.o. continuous...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinbild, S, Mross, K, Frost, A, Morant, R, Gillessen, S, Dittrich, C, Strumberg, D, Hochhaus, A, Hanauske, A-R, Edler, L, Burkholder, I, Scheulen, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360263/
https://www.ncbi.nlm.nih.gov/pubmed/18040273
http://dx.doi.org/10.1038/sj.bjc.6604064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360263/
https://www.ncbi.nlm.nih.gov/pubmed/18040273
http://dx.doi.org/10.1038/sj.bjc.6604064

Ejemplares similares